How do Mary Thistle’s 74,913-share Aktis Oncology stock options vest?

For the 74,913-share option, 25% of the original number of shares vests on January 15, 2026, and 1/48th of the original number of shares vests in monthly installments thereafter, subject to her continuous service through each vesting date.

Aktis Oncology (AKTS) director details stock option awards in Form 3 filing

Q: What role does Mary Thistle have at Aktis Oncology (AKTS)?

Mary Thistle is reported as a director of Aktis Oncology, Inc. in this Form 3 filing, with no officer title and not listed as a 10% owner.

Q: What stock options does Mary Thistle report holding in Aktis Oncology (AKTS)?

She reports beneficial ownership of two stock options (rights to buy common stock) : one for 74,913 shares at $10.66 per share expiring on January 14, 2035, and another for 18,933 shares at $18 per share expiring on January 7, 2036.

Q: When do Mary Thistle’s 18,933 Aktis Oncology stock options vest?

The option covering 18,933 shares is scheduled to vest in full on January 8, 2027 , provided that Mary Thistle continues her service with Aktis Oncology through that vesting date.

Q: Are Mary Thistle’s reported Aktis Oncology stock options held directly or indirectly?

The insider data describe both stock option holdings as direct (D) ownership, with no separate entity or indirect ownership structure noted.

Q: What is the event date for Mary Thistle’s Form 3 filing for Aktis Oncology (AKTS)?

The Form 3 identifies January 8, 2026 as the Date of Event Requiring Statement for reporting Mary Thistle’s stock option holdings.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Aktis Oncology, Inc. director Mary Thistle filed an initial ownership report showing she beneficially owns two stock option awards for common stock as of January 8, 2026. One option covers 74,913 shares at an exercise price of $10.66 per share, expiring on January 14, 2035. The filing notes that 25% of this option vests on January 15, 2026, with the remainder vesting in equal monthly installments thereafter, subject to continued service. A second option covers 18,933 shares at an exercise price of $18 per share, expiring on January 7, 2036, and is scheduled to vest in full on January 8, 2027, also conditioned on her continuous service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Thistle Mary

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 74,913 shares (Direct)

Footnotes (1)

25% of the original number of shares subject to the option shall vest on January 15, 2026, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.

Understanding Insider Trading Forms →

01/08/2026 - 08:57 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Thistle Mary

(Last)

(First)

(Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	01/14/2035	Common Stock	74,913	$10.66	D
Stock Option (Right to Buy)	⁽²⁾	01/07/2036	Common Stock	18,933	$18	D

Explanation of Responses:

1. 25% of the original number of shares subject to the option shall vest on January 15, 2026, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

2. The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Mary Thistle	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What role does Mary Thistle have at Aktis Oncology (AKTS)?

Mary Thistle is reported as a director of Aktis Oncology, Inc. in this Form 3 filing, with no officer title and not listed as a 10% owner.

What stock options does Mary Thistle report holding in Aktis Oncology (AKTS)?

She reports beneficial ownership of two stock options (rights to buy common stock): one for 74,913 shares at $10.66 per share expiring on January 14, 2035, and another for 18,933 shares at $18 per share expiring on January 7, 2036.

When do Mary Thistle’s 18,933 Aktis Oncology stock options vest?

The option covering 18,933 shares is scheduled to vest in full on January 8, 2027, provided that Mary Thistle continues her service with Aktis Oncology through that vesting date.

Are Mary Thistle’s reported Aktis Oncology stock options held directly or indirectly?

The insider data describe both stock option holdings as direct (D) ownership, with no separate entity or indirect ownership structure noted.

What is the event date for Mary Thistle’s Form 3 filing for Aktis Oncology (AKTS)?

The Form 3 identifies January 8, 2026 as the Date of Event Requiring Statement for reporting Mary Thistle’s stock option holdings.